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The purpose of this study was to determine health-related quality of life (HRQoL), fatigue, and 
posttraumatic growth (PTG) among patients with breast or prostate cancer during and following 
radiation therapy (RT). A total of 91 patients completed measures at three time points as follows: 
one or two weeks before the start of RT, in the fifth/sixth week of treatment, and four to six weeks 
post-treatment. Consistent with the previous literature, the results of this study revealed that RT 
was associated with declines in global HRQoL, Physical Well-being, Social/Family Well-being, 
and Functional Well-being, as well as an increase in fatigue. By four to six weeks post-treatment, 
these factors improved significantly and returned to baseline levels with the exception of 
Social/Family Well-being. The PTG total score and almost all of its subscale scores did not change 
significantly during the period of the study. However, the subscale of Spiritual Change for PTG 
significantly increased during the RT, and sustained this improvement at four to six weeks post-
treatment. A significant negative correlation was found between Physical Well-being and PTG 
total score, whereas a significant positive correlation was revealed between Social/Family Well-
being and PTG total score. The results from this analysis suggest that a significant decrease in 
HRQoL is evident in the fifth/sixth week of RT treatment. However, recovery of HRQoL occurs as 
quickly as a few weeks after the end of treatment. Moreover, patients with high ratings of 
Social/Family Well-being experience more positive psychological changes (PTG) resulting from 
the cancer experience.  
 





Recently, oncology and other divisions of medicine have placed great 
emphasis on measuring patients’ health-related quality of life (HRQoL), which is 
an important indicator of treatment outcomes and provides information about the 
side effects of treatment (De Graeff et al. 1999; Müller et al. 2011; Wengström et 
al. 2000). Moreover, HRQoL is a relevant determinant of cancer patients’ 
judgments and their adherence to oncological treatments (Frick et al. 2007). 
HRQoL is usually regarded as a multidimensional construct that includes several 
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core domains, such as (1) mental functioning; (2) physical functioning; (3) role 
functioning; and (4) social functioning (Bowling 2001).  
Radiotherapy (RT) is an increasingly used oncological treatment (Jones et 
al. 2011; Owen et al. 2006), with growing attention paid to its effects on HRQoL. 
Studies with RT recipients have measured HRQoL using the European 
Organization for Research and Treatment of Cancer Quality of Life Questionnaire 
(EORTC QOL-C30) (Dagnelie et al. 2007; Kenny et al. 2000; Lee et al. 2008; 
Stone et al. 2001), the Functional Assessment of Cancer Therapy Scale (FACT) 
(Deshields et al. 2005; Lee et al. 2001), and the Short Form-36 (SF-36) 
questionnaire (Madalinska et al. 2001; Stanton et al. 2001). These studies can be 
divided into the following two groups: half assess changes in HRQoL before, 
during, and after RT using a longitudinal design (e.g., Stone et al. 2001), whereas 
the other half compare the HRQoL of RT recipients to non-recipients (e.g., 
Madalinska et al. 2001) or RT recipients to healthy comparison subjects (e.g., 
Hann et al. 1998).   
The number of longitudinal studies examining the quality of life of cancer 
patients during and after RT is, surprisingly, quite low. Several studies have 
shown that HRQoL significantly declines during RT, and then significantly 
improves some weeks after the treatment has ended. Deshields et al. (2005) found 
that breast cancer patients reported low levels of HRQoL at the conclusion of RT, 
but by two weeks post-treatment, their quality of life improved significantly and 
remained relatively stable at six months post-treatment. This finding suggests that 
psychological recovery occurs within a short time post-treatment. Stone et al. 
(2001) investigated HRQoL in a group of breast and prostate cancer patients 
receiving RT. They reported that there was a significant deterioration of global 
quality of life and some of its subscales (e.g., role functioning, cognitive 
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functioning, and social functioning) between two points of measurement, which 
were pre-treatment (immediately prior to treatment) and within one week of the 
completion of RT. Another study found the same results with early-stage breast 
cancer patients (Jansen et al. 2000). Wengström et al. (2000) revealed a small 
decline in HRQoL during RT, but post-treatment scores seemed to equalize at 
follow-up measures (two weeks and three months after RT). A study by Dow and 
Lafferty (2000) demonstrated that overall quality of life and its subdomains (e.g., 
social, family, and psychological/spiritual functioning) declined from the start of 
RT to the midpoint of treatment, and then improved by six months after treatment 
ended (except for social functioning, which remained at a level that was lower 
than reported at the start of RT). By contrast, a number of studies have found that 
patients’ quality of life remains unchanged during radiation treatment (Back et al. 
2005; Lee et al. 2001; Lee et al. 2008). However, most of these studies did not 
measure HRQoL during RT, only before RT and after RT ended.  
HRQoL declines during RT partly because RT may make existing 
symptoms worsen or may produce new physical symptoms (side effects) 
(Wengström et al. 2000). Fatigue is a common, highly disruptive complaint of 
patients undergoing external RT (Ahsberg and Fürst 2001), and its prevalence 
rates among patients receiving RT can reach 70% or more (Danjoux et al. 2007; 
Janaki et al. 2010; Jereczek-Fossa et al. 2002). A number of studies have 
demonstrated that fatigue increases during the course of RT, and then returns to 
pre-treatment levels several months after the completion of RT (Jansen et al. 
2000; Lee et al. 2008; Stone et al. 2001). In a study by Wengström et al. (2000), 
fatigue worsened as the course of RT progressed, with a prevalence rate of over 
85% among breast cancer patients in the third and fifth weeks of treatment (87% 
and 90%, respectively). The pre-treatment prevalence rate (63%) returned by three 
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months post-treatment. Fatigue has a relevant effect on patients’ well-being, as it 
has been found to be the strongest determinant of overall quality of life (Dagnelie 
et al. 2007). Lee et al. (2008) revealed similar results by showing that fatigue is 
highly predictive of lower quality of life upon completion of RT and also at seven 
months after treatment ended. Moreover, fatigue is the most frequently mentioned 
symptom during RT (Wengström et al. 2000).       
The diagnosis and treatment of cancer includes potentially psychologically 
traumatic experiences for patients. Individuals have to adapt to symptoms and side 
effects, which may cause meaningful disruptions across several life domains 
(Bellizzi et al. 2007; Mols et al. 2009). However, a growing body of recent 
literature has reported that a significant percentage of cancer patients 
(approximately 70-90%) also experience positive life changes, namely 
posttraumatic growth (PTG) (Cordova et al. 2007; Lelorain et al. 2010; 
Schroevers and Teo 2008). The concept of PTG refers to positive changes that 
derive from struggling with highly stressful life events. These positive changes 
can be classified into the following five major categories: (1) a greater 
appreciation of life and a changed sense of priorities, (2) more meaningful 
relationships with others, (3) an increased sense of personal strength, (4) new 
possibilities for one’s life, and (5) a richer existential and spiritual life (Tedeschi 
and Calhoun 2004).  
In psycho-oncological research, HRQoL is sometimes positively related to 
PTG (Bower et al. 2005; Penedo et al. 2006; Urcuyo et al. 2005). For example, 
Lelorain et al. (2010) demonstrated that mental health and vitality subscales of 
overall quality of life were significantly positively related to PTG. Carver and 
Antoni (2004) reported in a longitudinal study that initial PTG predicted a higher 
quality of life five to eight years after diagnosis in breast cancer patients. In spite 
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of these results, most studies have not revealed any significant associations 
between HRQoL and PTG (Dunn et al. 2011; Kinsinger et al. 2006; Park et al. 
2010). 
In the case of cancer, the traumatic stressor is complex because it may 
contain the diagnosis, severity and prognosis of cancer, as well as oncological 
treatments and their side effects (Sumalla et al. 2009). Some studies have tried to 
explore the nature of the relationship between the types of oncological treatments 
and PTG. In studies with cancer patients, receiving RT did not generally relate to 
PTG (Cordova et al. 2007; Mystakidou et al. 2008; Thombre et al. 2010). 
However, these cross-sectional studies measured PTG several months or years 
after the RT treatment, but not before, during, and after the RT. To date, no study 
in the scientific literature has explored changes in PTG before, during, and after 
the course of RT treatment.   
The aim of the current longitudinal study was to investigate the patterns of 
change in HRQoL, fatigue, and PTG with a sample of breast and prostate cancer 
patients who were undergoing RT. First, we hypothesized that cancer patients’ 
quality of life would significantly decrease during RT and that it would 
significantly improve after the treatment ended. Second, we hypothesized that 
PTG would not be related to HRQoL. Third, we assumed that the fatigue reported 
by patients would worsen during the course of RT and that it would decrease after 





The study sample was recruited from the Department of Radiotherapy at the 
University of Debrecen. The inclusion criteria for the study were the following: 
(1) no previous cancer history; (2) primary breast or prostate cancer without 
distant metastases; (3) imminent initiation of external beam radiotherapy; and (4) 
more than 18 years of age. Our sample consisted of patients with either breast or 
prostate cancer, given that these diseases have similar RT treatment regimens and 
cause similar impairments in the quality of life (Ransom et al. 2008). All 
questionnaires were administered three times. For the first wave, eligible patients 
were identified and then provided with information about the study by a 
psychologist after a session of radiation simulation (one or two weeks before the 
start of RT). Participants completed a written informed consent form and a 
questionnaire packet (T1). For the second and third waves, questionnaires were 
mailed to the patients in the fifth/sixth week of RT treatment (T2) and four to six 
weeks after the end of RT (T3). The study was approved by the Medical Ethical 




HRQoL. Quality of life was measured with the Hungarian translation 
(Webster et al. 2003) of the Functional Assessment of Cancer Therapy-General 
Questionnaire (FACT-G version 4; Cella et al. 1993), which was originally 
developed for and widely used with adult patients with any type of tumor. It 
consists of the following four subscales: Physical Well-being (PWB), Emotional 
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Well-being (EWB), Social/Family Well-being (SFWB), and Functional Well-
being (FWB). We explored feelings of fatigue with the following two individual 
items from the Physical Well-being subscale: “I have a lack of energy” and “I am 
forced to spend time in bed”. FACT-G items were rated on a five-point Likert 
scale ranging from 0 (not at all) to 4 (very much). A total score was derived by 
summing the four subscale scores (range 0-108). Higher scores on the 
questionnaire indicate better HRQoL. For the present sample, the Cronbach’s 
alphas for the FACT-G total score were 0.73 (T1), 0.69 (T2), and 0.80 (T3).   
 
PTG. The Posttraumatic Growth Inventory (PTGI; Tedeschi and Calhoun 
1996) is a 21-item self-report inventory of a person’s perceptions of positive 
changes after a traumatic life event. The original English version assesses the 
following five domains of growth: Relating to Others, New Possibilities, Personal 
Strength, Spiritual Change, and Appreciation of Life. Items were rated on a six-
point Likert scale ranging from 0 (I did not experience this change as a result of 
my cancer) to 5 (I experienced this change to a great degree as a result of my 
cancer). Adding up the scores of the five subscales yields a PTGI total score 
(range 0-105). The Hungarian version of the PTGI (Kulcsár et al. 2006) with the 
original 21 items and five subscales was used to measure cancer-related PTG. In 
this sample, the internal consistencies for the PTGI total scores were 0.81 (T1), 
0.87 (T2), and 0.88 (T3).   
 
Socio-demographic and medical variables. The following socio-
demographic variables were assessed: age, gender, marital status, and education. 
The following medical variables were derived from patients’ medical charts: the 
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stage of the cancer, the type of treatment received (e.g., type of surgery, hormonal 
therapy, chemotherapy), and the length of time elapsed since diagnosis.  
 
Statistical analyses 
Descriptive statistics were measured for normalcy, and means, standard 
deviations, ranges, and counts for the variables were calculated. Chi-square tests, 
t-tests or Mann-Whitney U tests were used to determine whether those patients 
who did not complete all of the assessments differed from those who completed 
all of the assessments with regard to socio-demographic and medical variables. 
The relationships between the socio-demographic, medical variables and the PTG 
and FACT-G were determined using t-tests, the Mann-Whitney U test, Welch's t-
tests, analyses of variance (ANOVA), or the Kruskal-Wallis test. Pearson or 
Spearman correlations were calculated to reveal associations between the FACT-
G and PTG. Pairwise comparisons of the two individual fatigue-related items’ 
scores at T1, T2, and T3 were completed with Wilcoxon paired signed-rank tests. 
Finally, repeated measures analyses of variance were conducted to examine 
whether there were significant changes in FACT-G scores and PTGI scores 
throughout the duration of the study. Bonferroni’s method was used for multiple 
comparisons of FACT-G scores and PTGI scores at T1, T2, and T3. The 





A total of 152 individuals were approached to participate in this study 
before RT (T1) (84.2% female patients; mean age: 59.1 years, SD=10.7, range 34-
80). Of the 152 patients, 91 (59.8%) completed questionnaires at T2 and T3 
(84.6% female patients; mean age: 58.7 years, SD=10.6, range 34-78). Attrition 
bias was examined by testing whether any systematic differences existed between 
patients missing at the follow-ups and patients who participated in all of the 
assessments. No significant differences were found between the two samples in 
socio-demographic and medical variables. Of the 91 patients, 65.9% were married 
or lived with a partner (N=60), and a significant number reported having a 
secondary education (N=60, 65.9%). The mean length of time since diagnosis was 
111.2 days (SD=77.5, range 8-387). The disease stages at diagnosis were Stage I 
(46.1%), Stage II (36.3%), Stage III (14.3%), or Stage IV (3.3%). All patients had 
undergone some form of surgery, but only 15.4% (N=14) had undergone a 
mastectomy or prostatectomy. Many patients were treated by chemotherapy 
(N=43, 47.3%) and a majority were treated by hormonal therapy (N=66, 72.5%) 
(see Table 1).  
 
Relationships of socio-demographic and medical variables to HRQoL 
and PTG 
Preliminary analyses were conducted to examine whether socio-
demographic or medical variables were related to HRQoL or PTG at the three 
measurement times. We found that neither PTGI total scores nor FACT-G total 
scores were significantly associated with any of the socio-demographic (i.e., age, 
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gender, education, and marital status) or medical (i.e., stage, 
mastectomy/prostatectomy, hormonal therapy, chemotherapy, and time since 
diagnosis) variables at T1, T2, and T3.    
 
Changes in HRQoL 
The means and standard deviations for the FACT-G total score and the 
FACT-G subscales are presented in Table 2. Overall p values and p values for the 
pairwise comparisons are also reported in Table 2. The FACT-G total scores 
significantly declined between T1 and T2, and then significantly increased 
between T2 and T3. No significant difference was found between the FACT-G 
total scores at T1 and T3. The same pattern was found for the PWB subscale: 
scores significantly decreased during RT (T2), and then returned to baseline levels 
four to six weeks after RT ended (T3). During RT (T2), the SFWB score was 
significantly lower than the baseline SFWB score (T1), and it remained low at the 
time of the third measurement (T3). EWB did not significantly change during the 
time period of the study. The FWB scores significantly decreased between T1 and 
T2, and then showed nonsignificant improvement by T3. Comparisons of the 
baseline HRQoL scores (T1) and the HRQoL scores at T3 revealed that none of 
the subscale scores at four to six weeks after RT ended (T3) were significantly 
different from the baseline scores (T1), except for the SFWB score. This result 
means that all of the well-being scores returned to the baseline scores four to six 
weeks after RT. 
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Changes in PTG 
The means and standard deviations for the PTGI total score and the PTGI 
subscales are presented in Table 2. Overall p values and p values for the pairwise 
comparisons are also reported in Table 2. The PTGI total score and the subscales 
for New Possibilities, Personal Strength, and Relating to Others remained 
relatively stable throughout the measurements. The Appreciation of Life scores 
increased but not significantly at T2 compared with T1, and then significantly 
declined between T2 and T3. The Spiritual Change scores significantly increased 
during RT (T2), and this improvement was maintained four to six weeks after RT 
ended (T3).   
 
Relationships between HRQoL and PTG 
There were no statistically significant correlations between the PTGI total 
scores and the FACT-G total scores (at T1, T2, and T3) (see Table 3). However, 
significant negative correlations were found between PWB scores and PTGI total 
scores. The strongest correlation was between the PWB score at T1 and the PTGI 
total score at T3 (r=-0.26, p<0.01). Moreover, significant positive correlations 
were revealed between SFWB subscales and PTGI total scores at all points of 
measurement. The strongest correlation was between the SFWB subscale and the 
PTGI total score at T1 (r=0.34; p<0.01). 
 
Changes in fatigue 
Changes in feelings of fatigue were calculated by separating the two fatigue-
related items from the PWB subscale of the FACT-G (see Table 4). The results 
derived from these two items show the same pattern of change, in that patients felt 
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significantly more fatigue during RT (T2) compared with the baseline 
measurement (T1). However, fatigue significantly decreased by four to six weeks 
after RT ended (T3). Thus, the feeling of fatigue increased during RT, but it 
returned to the baseline level some weeks after the treatment ended.    
 
Discussion 
This study is the only one available in the psycho-oncological literature that 
examined the relationship between HRQoL and PTG among breast and prostate 
cancer patients undergoing RT. We used a longitudinal design to measure HRQoL 
and PTG before, during (in the fifth/sixth week of the treatment), and after RT 
(four to six weeks after the end of treatment).  
According to our results, neither PTGI total scores nor FACT-G total scores 
were significantly associated with any of the socio-demographic or medical 
variables during the study period. We found a significant deterioration in overall 
quality of life (FACT-G total) and PWB at the fifth/sixth week of RT. However, 
by four to six weeks after RT had ended, both of these variables showed 
improvement and had returned to their baseline levels. The FWB score decreased 
during RT, and then started to increase by four to six weeks post-treatment, but 
only to a small degree. 
EWB was the only domain of HRQoL that remained unchanged, which is in 
line with results from a previous study reporting that RT recipients and healthy 
comparison subjects do not differ with regard to levels of anxiety and depressive 
symptoms (Hann et al. 1998). This result may suggest that a relative emotional 
equilibrium was typical for these patients during and shortly after RT in contrast 
with the upheaval caused by the diagnosis.  
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We observed a significant decline in the SFWB score during RT and that 
this was the only domain of HRQoL that did not return to the baseline level after 
RT ended. This result is in line with the study of Dow and Lafferty (2000) that 
found that social functioning significantly decreased during RT and remained 
lower by six months post-treatment. Although the specific cause of this decrease 
in SFWB could not be determined in this study, it is possible that during and 
shortly after RT patients temporarily withdraw from their social support system 
because of the experienced side effects caused by the RT.  
Overall, we found that all of the well-being scores (except for EWB) 
significantly decreased during RT. However, by four to six weeks after RT had 
ended, all of them improved and returned to their baseline scores (except for 
SFWB, which did not return). The changes in HRQoL within this sample were 
similar to those reported in previous studies (Deshields et al. 2005; Wengström et 
al. 2000). For example, Stone et al. (2001) observed significant decreases in role, 
cognitive, and social functioning by the last week of RT. They also found that 
emotional functioning did not change during this period. A study conducted by 
Dow and Lafferty (2000) revealed that, by the midpoint of RT, significant 
deterioration had occurred in social, family, and psychological/spiritual 
functioning. By six months post-treatment, all of these factors improved with the 
exception of social functioning, which remained low.  
Our hypothesis that fatigue reported by patients may worsen during the 
course of RT was supported by the results of this study. A clinically significant 
increase in fatigue was found during the RT, but it returned to the baseline level 
four to six weeks after the end of treatment. This finding is consistent with some 
previous studies that found the same pattern of change in fatigue among cancer 
patients receiving RT (Jansen et al. 2000; Lee et al. 2008; Stone et al. 2001).  
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The overall PTG and most of its subscales did not change significantly 
during the time period of this study. Only two subscales were exceptions: 
Appreciation of Life and Spiritual Change. Appreciation of Life showed an 
increasing trend during RT, and then it significantly declined four to six weeks 
after the treatment ended. It is possible that receiving RT treatment constantly 
reminds a person of his/her illness and the possible danger of death, which can 
enhance feelings of appreciation and respect for life. However, after the treatment 
this “memento” may disappear, making the Appreciation of Life decrease. 
Moreover, Spiritual Change significantly increased during RT, and this 
improvement was maintained four to six weeks post-treatment. RT treatment may 
serve as a reminder of the threat of death, which can precipitate sensitivity to the 
transcendent. This experience may continue after the RT, as the signs of recovery 
(e.g., better HRQoL) confirm the relationship with the transcendent (e.g., God).   
As expected, no significant associations were found between the PTGI total 
scores and the FACT-G total scores. Nevertheless, we found significant negative 
correlations between PWB and PTGI total scores: people with lower PWB 
reported greater PTG. Physical symptoms may remind patients of the threat 
caused by their illness and, as other studies have shown, greater feelings of threat 
may prompt more positive changes (PTG) (Barakat et al. 2006; Lechner et al. 
2003). In addition, positive correlations were reported between SFWB and PTGI 
total scores, indicating that patients with greater perceived social support 
experienced more positive changes. Several studies have found that social support 
is a determining factor in finding benefits in a life-threatening illness (Bellizzi et 
al. 2007; Dunn et al. 2011; Schroevers et al. 2010). The possibility for patients to 
disclose negative cancer–related emotions (e.g., fear) and the empathy and 
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compassion coming from family members and friends can contribute to greater 
awareness of positive changes that result from an illness.  
Although we found significant impairment in HRQoL during RT, it is 
important to note that RT has a highly relevant role in the curative and palliative 
treatment of cancer. For example, RT can significantly decrease the incidence of 
intra-breast tumor reappearance in the case of breast cancer (Veronesi et al. 2001). 
Moreover, this decline in quality of life is only transient, as Deshiels et al. (2005) 
demonstrated that psychological “recovery” occurs two weeks after the end of RT. 
It may be important for future research to compare changes in HRQoL during 
chemotherapy to changes in HRQoL during RT, since as Conner-Spady et al. 
(2005) found, the pattern of change in HRQoL during chemotherapy can be 
similar to our results.  
The present study has several limitations. First, the sample consisted 
primarily of female breast cancer patients (partly because prostate cancer patients 
were more likely to refuse study participation). It limits the generalizability of the 
results to other cancer populations. Second, we measured fatigue with two 
individual items of the PWB subscale. A questionnaire that specifically assesses 
fatigue may be more useful and valid for exploring this relevant side effect of RT. 
Third, the time interval for this study was relatively short. A longitudinal study 
that lasts several years could explore both the short-term and long-term side 
effects of RT. Fourth, our study did not make a baseline assessment of HRQoL 
and PTG at the time of diagnosis, which would have provided a fuller picture of 
the changes in HRQoL and PTG.  Fifth, HRQoL does not provide information 
about all of the effects of treatment that study participants experience during RT. 
Therefore, the application of a radiotherapy-specific instrument which measures 
the side effects of RT would be highly recommended.  
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The results of our study have important clinical implications. Patients with 
breast and prostate cancers should be informed about the probable side effects of 
RT and their effective management before the start of treatment. For example, 
exercise (e.g., walking) is a highly recommended and useful technique for 
alleviating fatigue and improving physical functioning during and after RT 
(Hwang et al. 2008; Mock et al. 2001). In addition, given that SFWB was the only 
domain of HRQoL that remained low after treatment, health care professionals 
should emphasize promotion of the social well-being of patients undergoing RT. 
This can be realized by either organizing support groups (Lazányi et al. 2010) or 
providing personal counseling, which could be helpful to avoid or decrease the 
social withdrawal of RT recipients. Our results show that only those patients who 
feel higher SFWB are able to recognize the psychological benefits (PTG) 
resulting from the cancer.  
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Table 1 Socio-demographic and medical characteristics of the sample (N=91) 
  Female   Male   Total 
Variable M SD % 
 
M SD % 
 










           Female 
          
84.6 
Male 
          
15.4 
Marital status 




   
71.4 






   
28.6 




           Primary education or less 
  
23.4 
   
28.6 





   
64.3 





   
7.1 
   
9.9 
Cancer site 
           Breast  
          
84.6 
Prostate 
          
15.4 
Stage 




   
0 






   
57.2 






   
21.4 





   
21.4 
   
3.3 





 Type of treatment 





   
21.4 






   
92.8 






   
7.1 
   
47.3 
20 
Note:   
a 
Genders differ at p<0.01. 
b 
Includes single, divorced, and widowed patients. 
c 
Primary education: primary school; Secondary education: secondary school, trade school, technical college, grammar school; Higher education: 
college, university. 
d 
Genders differ at p<0.001. 
e 
















Table 2 Repeated measures analysis of variance of quality of life and posttraumatic growth 




  T1 T2 T3 
 
Overall T1 vs. T2 T2 vs. T3 T1 vs. T3 


























EWB 17.4 (5.2) 17.1 (5.2) 17.6 (5.5) 
 
0.985 1.000 0.369 1.000 







PTGI 63 (23.3) 67.5 (22.3) 64.9 (23.9) 
 
0.067 0.134 0.222 0.945 







NP 12.3 (7.7) 13.9 (6.8) 13.4 (6.9) 
 
0.051 0.115 0.819 0.284 
PS 13.3 (4.7) 13.6 (4.5) 13.5 (4.8) 
 
0.774 1.000 1.000 1.000 








RO 24 (8.9) 24.6 (7.4) 23.7 (8.1) 
 
0.437 1.000 0.370 1.000 
Abbreviations: SD=standard deviation; T1=Time 1 (before radiotherapy); T2=Time 2 (the fifth/sixth week of radiotherapy); T3=Time 3 (four to six weeks after 
radiotherapy); FACT-G=Functional Assessment of Cancer Therapy-General total score; PWB=Physical Well-being; SFWB=Social/ Family Well-being; 
EWB=Emotional Well-being; FWB=Functional Well-being; PTGI=Posttraumatic Growth Inventory total score; AL=Appreciation of Life; NP=New Possibilities; 
PS=Personal Strength; SC=Spiritual Change; RO=Relating to Others. 
* P values of repeated measures analyses of variance and Bonferroni’s multiple comparisons.  
†








Table 3 Intercorrelations between health-related quality of life and posttraumatic growth at Time 1, Time 2, and Time 3 
HRQoL 
domains PTGI (T1) PTGI (T2) PTGI (T3) 
FACT-G (T1)  0.10  -0.08  -0.05 
FACT-G (T2)  0.01  0.05  0.00 
FACT-G (T3)  -0.01  0.04  0.00 
PWB (T1)  -0.16  -0.22*  -0.26** 
PWB (T2)  -0.16  -0.09  -0.18 
PWB (T3)  -0.17  -0.19  -0.21* 
SFWB (T1)  0.34**  0.05  0.11 
SFWB (T2)  0.28  0.26*  0.29** 
SFWB (T3)  0.35  0.27*  0.27** 
EWB (T1)  -0.00  -0.06  -0.08 
EWB (T2)  -0.04  -0.14  -0.09 
EWB (T3) 0.09  0.08  -0.10 
FWB (T1)  0.14 0.00  0.09  
FWB (T2)  0.02  0.14  0.05 
FWB (T3)  -0.03  0.16  0.12 
Abbreviations: HRQoL=health-related quality of life; PTGI=Posttraumatic Growth Inventory total score; T1=Time 1 (before radiotherapy); 
T2=Time 2 (the fifth/sixth week of radiotherapy); T3=Time 3 (four to six weeks after radiotherapy); FACT-G=Functional Assessment of Cancer 








Table 4 Changes in fatigue 
  Mean (SD)   p* 
  T1 T2 T3 
 
T1 vs. T2 T2 vs. T3 T1 vs. T3 
I have a lack of energy
#







I am forced to spend time in bed
#







Abbreviations: SD=standard deviation; T1=Time 1 (before radiotherapy); T2=Time 2 (the fifth/sixth week of radiotherapy); T3=Time 3 (four to six 
weeks after radiotherapy).  
*
 P values of Wilcoxon paired signed-rank tests. 
# 
Two individual fatigue-related items from the Physical Well-being subscale of Functional Assessment of Cancer Therapy-General Questionnaire. 
†
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